Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Telmisartan 40 mg once daily for 12 weeks: Group 1 Telmisartan 40 mg once in the morning for 12 weeks
Intervention2: Telmisartan 40 mg once daily for 12 weeks: Group 2 Telmisartan 40 mg
Sponsors
Non funded study All India Institute of medical sciences Jodhpur
Eligibility
Inclusion criteria
Inclusion criteria: Age group 18 to 65 years Newly diagnosed cases of Stage 1 hypertension Patients willing to undergo Ambulatory Blood Pressure Monitoring ABPM and Automatic Office Blood Pressure AOBP measurement
Exclusion criteria
Exclusion criteria: Shift workers Heavy drinkers intake and gt 80 gm per day Heavy smokers 20 cigarettes per day Patients with Type 1 diabetes mellitus Patients with a history of cardiovascular disorders like unstable angina heart failure arrhythmia, myocardial infarction, and coronary revascularization Patients with a history of stroke Patients with impaired kidney function Pregnant women Patients using non-steroidal anti-inflammatory drugs (NSAIDs) regularly
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| compare the efficacy of telmisartan in controlling the 24-hour mean systolic blood pressure and diastolic blood pressure after 12 weeks of administration as a single morning dose a single bedtime dose and divided morning and bedtime dosesTimepoint: compare the efficacy of telmisartan in controlling the 24-hour mean systolic blood pressure and diastolic blood pressure after 12 weeks of administration as a single morning dose a single bedtime dose and divided morning and bedtime doses | — |
Secondary
| Measure | Time frame |
|---|---|
| compare the differential effects of telmisartan on extreme nocturnal blood pressure dipping patterns specifically focusing on risers individuals exhibiting higher nocturnal BP than daytime BP and extreme dippers individuals exhibiting a marked nocturnal BP decline when administered as a single morning dose a single bedtime dose and divided morning and evening dosesTimepoint: Baseline and after 12 weeks;compare the efficacy of telmisartan in controlling nocturnal mean SBP and mean DBP when administered as a single morning dose a single bedtime dose and divided morning and bedtime doses after 12 weeksTimepoint: Baseline and after 12 weeks;compare the efficacy of telmisartan in controlling the mean diurnal SBP and DBP when administered as a single morning dose a single bedtime dose and divided morning and bedtime doses after 12 weeksTimepoint: Baseline and at 12 weeks;compare the impact of telmisartan on fasting blood glucose creatinine uric acid, cholesterol and triglyceride levels when administered as a single morning dose a single bedtime dose and divided morning and bedtime dosesTimepoint: Baseline and after 12 weeks;compare the safety profile including adverse drug reactions of telmisartan when administered as a single morning dose a single bedtime dose and divided Morning and bedtime dosesTimepoint: Baseline and after 12 weeks | — |
Countries
India
Contacts
Public ContactDR RIMPLE JEET KAUR
All India institute of medical sciences jodhpur
Outcome results
None listed